Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news.

That's what has happened this year to Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, with its stock price up by nearly 300% since January. Madrigal Pharmaceuticals (NASDAQ: MDGL), another mid-cap drugmaker, hasn't been so lucky in 2024 despite hitting an important milestone; its shares are up by a much less impressive 7% year to date.

That said, Viking and Madrigal are still early in the game. Both could be just at the beginning of their growth journeys. Which one looks like the better option for long-term investors right now? Let's find out.

Continue reading

Source Fool.com